Trametinib is a kinase inhibitor targeting MEK1 and MEK2, approved for the management of metastatic or BRAF V600E- or BRAF V600K-mutated unresectable melanoma or as adjuvant treatment at an oral dosage of 2 mg a day [41]. Here, MAP2K2 is linked to melanoma.